Nowadays, breast cancer has replaced the lung cancer to become the leading cancer in the world which seriously threatens women's health. The anti-HER2 therapy is the cornerstone treatment for HER2-positive breast cancer patients, and the approaches to overcoming drug resistance are closely explored by researchers. LEPU BIOPHARMA is now conducting a multi-center, open-label, dose escalation and expansion phase I clinical trial on the novel anti-HER2 anti-body drug conjugate (ADC) MRG002 therapy for HER2-positive advanced solid tumors to explore the safety, tolerance, efficacy and pharmacokinetic profiles of the MRG002 therapy in patients with HER2-positive advanced solid tumors. Of note, one patient (enrolled on May 10th 2021) has been reported to have liver metastasis resolved from 15.97 mm to 10.01 mm and has been assessed to achieve partial response (PR) only after receiving two cycles of MRG002 therapy. Actually, this patient used to receive 6 lines of treatments involving drugs such as Lapatinib and T-DM1 between November 21st 2017 and July 21st 2020 and never achieved response before. During the treatment session, the patients are well-tolerated and the adverse reactions are mostly rated as grade 1. As the follow-up prolongs, researchers will further observe the efficacy and safety profiles of the MRG002 therapy. We are looking forward to releasing more research findings and bringing new hopes for patients!

Source from China Medical Tribune